| pubmed-article:2366863 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0024518 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0054036 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0449450 | lld:lifeskim |
| pubmed-article:2366863 | lifeskim:mentions | umls-concept:C0205228 | lld:lifeskim |
| pubmed-article:2366863 | pubmed:issue | 6279 | lld:pubmed |
| pubmed-article:2366863 | pubmed:dateCreated | 1990-8-15 | lld:pubmed |
| pubmed-article:2366863 | pubmed:abstractText | Peptides bound to class I or class II major histocompatibility complex (MHC)-encoded molecules are ligands for the antigen-specific T-cell receptor of T-cells carrying the CD8 and CD4 antigens, respectively. MHC class I-restricted T cells generally recognize peptides derived from processing of endogenously synthesized cellular antigens, whereas class II-restricted T cells usually recognize peptides derived from exogenous antigens entering antigen presenting cells. Accordingly, two separate pathways of antigen processing and presentation have been proposed. The fungal metabolite brefeldin A (BFA), an inhibitor of protein transport from the endoplasmic reticulum, inhibits presentation of endogenous antigens for MHC-restricted T-cell recognition. The selectivity of BFA activity has been inferred to reflect presentation of a given antigen processed through the cytosolic or the endocytic route. Here we show that BFA also greatly inhibits the presentation of exogenous protein antigens by MHC class II molecules to T cells, indicating a broader effect of this drug on antigen presentation and an additional similarity between the two processing pathways. As cycloheximide, a protein synthesis inhibitor, also inhibits presentation of protein antigens to class II-restricted T cells, the data indicate that peptides generated by processing of exogenous proteins binds to newly synthesized class II molecules for presentation to T cells. | lld:pubmed |
| pubmed-article:2366863 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2366863 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2366863 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2366863 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2366863 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:2366863 | pubmed:issn | 0028-0836 | lld:pubmed |
| pubmed-article:2366863 | pubmed:author | pubmed-author:AdoriniLL | lld:pubmed |
| pubmed-article:2366863 | pubmed:author | pubmed-author:FuchsSS | lld:pubmed |
| pubmed-article:2366863 | pubmed:author | pubmed-author:AppellaEE | lld:pubmed |
| pubmed-article:2366863 | pubmed:author | pubmed-author:UllrichS JSJ | lld:pubmed |
| pubmed-article:2366863 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2366863 | pubmed:day | 5 | lld:pubmed |
| pubmed-article:2366863 | pubmed:volume | 346 | lld:pubmed |
| pubmed-article:2366863 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2366863 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2366863 | pubmed:pagination | 63-6 | lld:pubmed |
| pubmed-article:2366863 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:meshHeading | pubmed-meshheading:2366863-... | lld:pubmed |
| pubmed-article:2366863 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2366863 | pubmed:articleTitle | Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells. | lld:pubmed |
| pubmed-article:2366863 | pubmed:affiliation | Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland. | lld:pubmed |
| pubmed-article:2366863 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2366863 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2366863 | lld:pubmed |
